NASDAQ$AHCO

AdaptHealth Corp. · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Announced third quarter 2020 financial results, showing increased guidance for fiscal year 2020.

AdaptHealth Corp. reported strong third-quarter results, driven by employee dedication and strategic acquisitions, leading to increased financial guidance for fiscal year 2020.

  • Increased financial guidance for fiscal year 2020 for net revenue to $1.00 billion to $1.04 billion.
  • Adjusted EBITDA is expected to be $186 million to $194 million.
  • Adjusted EBITDA less Patient Equipment Capex is projected to be $124 million to $130 million.
  • Acquired several diabetes management and home medical equipment businesses in high-growth areas.

Headline financials

Total Revenue

$284M

Previous: $136M+108.4%
EPS (adj)

$0.05

Previous: -$0.16+131.3%
Capital Expenditures

-$22.8M

Previous: $3.71M-715.1%
Free Cash Flow

-$25.3M

Previous: -$4.32M-486.4%
Net Income

-$2.49M

Previous: -$154K-1511.3%
Operating Income

$13.3M

Previous: -$1.25M+1164.8%
Gross Profit

$43.7M

Previous: $25.3M+72.4%
Cash & Equivalents

$272M

Previous: $8.82M+2986.5%
Total Assets

$1.55B

Previous: $257M+503.5%
Stock-Based Comp

$5.5M

Previous: $400K+1275.5%

Revenue & EPS history

AdaptHealth · Revenue · Quarterly

$284M

Q3 2020+108.4%vs Q3 2019
Beat estimate in 4 of 9 quarters(44%)
ActualEstimate

Forward guidance

The company increased financial guidance for fiscal year 2020 and provided guidance for 2021.

Tailwinds

  • Net revenue to $1.00 billion to $1.04 billion.
  • Adjusted EBITDA to $186 million to $194 million.
  • Adjusted EBITDA less Patient Equipment Capex to $124 million to $130 million.
  • Net revenue of $1.30 billion to $1.40 billion for 2021.
  • Adjusted EBITDA of $260 million to $280 million for 2021.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

+0.6%

Avg return

Earnings day

+1.4%

Avg return

5 days after

+1.6%

Avg return

30 days after

52%

16 / 31 earnings

Positive

+34.6%

Q4 2023

Best reaction

-27.9%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-10.0%-13.4%-25.6%
Q4 2025-14.2%-11.1%+10.9%
Q3 2025+17.2%+4.5%+3.2%
Q1 2025+1.7%-1.4%+3.7%
Q4 2024+24.4%+33.1%+24.4%
Q3 2024+0.3%-0.6%-4.2%
Q2 2024-17.2%-14.1%+4.6%
Q1 2024-8.6%-8.8%+4.9%
Q4 2023+34.6%+37.9%+50.9%
Q3 2023-23.1%-18.6%-5.6%
Q2 2023+11.1%+4.4%-19.8%
Q1 2023-8.4%-12.2%-13.8%
Q4 2022-27.9%-27.9%-40.6%
Q3 2022-1.6%+8.4%+4.5%
Q2 2022-8.9%-8.2%-25.7%
Q1 2022+23.7%+42.2%+53.6%
Q4 2021+4.1%+2.3%+2.8%
Q3 2021-5.4%-7.2%-24.1%
Q2 2021+16.4%+13.4%+12.3%
Q1 2021-8.5%-14.9%-10.4%
Q4 2020+2.1%+12.4%+21.7%
Q3 2020+2.6%+0.6%+19.5%
Q2 2020+13.9%+18.0%+7.0%
Q1 2020+1.6%+5.8%+5.5%
Q4 2019+1.8%+1.4%-7.7%
Q3 2019-4.1%-4.9%-3.3%
Q2 2019+0.0%+0.0%-0.6%
Q1 2019+0.0%+0.0%+0.3%
Q4 2018+0.6%+0.7%+1.3%
Q3 2018+0.3%+0.1%+0.4%
Q2 2018+0.0%+0.3%+0.1%
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro